Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Operating Leases (2022 - 2025)

Ascentage Pharma Group International posted quarterly Operating Leases of $3.1 million for Q4 2025, down 25.64% year-on-year from $4.2 million in Q4 2024, and down 25.64% on a QoQ basis from $4.2 million in Q4 2024.

Ascentage Pharma Group International (AAPG) has 4 years of Operating Leases data on file, last reported at $3.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 25.64% year-over-year to $3.1 million; the trailing twelve-month figure through Dec 2025 stood at $3.1 million (down 25.64% YoY), and the FY2025 full-year result was $3.2 million, down 26.58% from the prior year.
  • Operating Leases for Q4 2025 stood at $3.1 million, down from $4.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $4.2 million in Q4 2024 and bottomed at $2.4 million in Q4 2022.
  • The 4-year median for Operating Leases is $3.1 million (2025), against an average of $3.2 million.
  • The widest annual swing landed in 2024, when Operating Leases surged 33.61%; it then fell 25.64% in 2025.
  • A 4-year view of Operating Leases shows it stood at $2.4 million in 2022, then jumped by 30.09% to $3.2 million in 2023, then jumped by 33.61% to $4.2 million in 2024, then dropped by 25.64% to $3.1 million in 2025.
  • The last three Operating Leases figures came in at $3.1 million (Q4 2025), $4.2 million (Q4 2024), and $3.2 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 3.13 Mn
Dec 31, 2024 4.21 Mn
Dec 31, 2023 3.15 Mn
Dec 31, 2022 2.42 Mn